| Drug Name |
Ziprasidone |
| Drug ID |
BADD_D02415 |
| Description |
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525]
Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537]
Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525] |
| Indications and Usage |
In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342] |
| Marketing Status |
approved |
| ATC Code |
N05AE04 |
| DrugBank ID |
DB00246
|
| KEGG ID |
D08687
|
| MeSH ID |
C092292
|
| PubChem ID |
60854
|
| TTD Drug ID |
D0R1JV
|
| NDC Product Code |
59762-1006; 72578-127; 0049-0354; 70771-1179; 70771-1181; 62135-993; 72578-125; 70771-1180; 72578-128; 57297-330; 59762-1012; 0049-0352; 62135-992; 0049-0358; 62135-991; 0049-0356; 70518-3376; 59762-1014; 62135-994; 70771-1182; 72578-126; 59762-1008 |
| UNII |
6UKA5VEJ6X
|
| Synonyms |
ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059 |
